VIRBAC CORPORATION NAMES ROBERT “MAC” MACGREGOR VICE PRESIDENT, INDUSTRIAL OPERATIONS
05/18/2015
Fort Worth, Texas (May 18, 2015) – Virbac Corporation today announced that Mr. Robert “Mac” MacGregor has been named Vice President, Industrial Operations, effective immediately. In this role, Mr. MacGregor will be responsible for North American Industrial Operations, encompassing planning, directing and coordinating all manufacturing activities, to efficiently supply customers based upon their needs and pharmaceutical/regulatory requirements.
Read more
VIRBAC CORPORATION STRENGTHENS SALES ORGANIZATION
04/02/2015
Fort Worth, Texas (April 2, 2015) – Virbac Corporation today announced the promotions of three individuals, Naomi Potts, Bryan Armstrong and Mary Jo McNeily to Sales Director Roles. In these new roles, they will report directly to Jim Van Proosdy, Vice President of Sales for Virbac U.S.
Read more
VIRBAC ANNOUNCES THE CLOSING OF THE SENTINEL® BRANDS FAMILY ACQUISITION IN THE U.S.
01/15/2015
Fort Worth, Texas (January 5, 2015) – Virbac announces the successful closing, on January 2nd, of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM®, previously marketed by Novartis Animal Health.
Read more
VIRBAC ANNOUNCES THAT IT HAS ENTERED INTO AGREEMENT WITH ELI LILLY AND COMPANY
10/27/2014
Fort Worth, Texas (October 27, 2014) – Virbac Corporation today announced that it has entered into an agreement with Eli Lilly and Company to acquire major U.S. veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.
Read more
VIRBAC CORPORATION NAMES ALAN TAYLOR VICE PRESIDENT OF BUSINESS DEVELOPMENT
07/15/2014
Fort Worth, Texas (July 15, 2014) – Virbac Corporation today announced that Dr. Alan Taylor has been named Vice President of Business Development, effective July 14, 2014. In this role, Dr. Taylor will be responsible for generating external growth for Virbac North America and the Commonwealth Countries, through the acquisition or licensing-in of new products, and through the merger and acquisitions of third party companies. Additionally, he will support the R&D internal organization through the licensing-in of opportunities of selected new actives or new technologies that could be further developed internally.
Read more